Several studies have revealed that the hyper-inflammatory response induced by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity …

This International Myeloma Working Group consensus updates the disease definition of
multiple myeloma to include validated biomarkers in addition to existing requirements of …

Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell
therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …

Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Virtually no progress has been made during more than 2 decades of clinical trials for
multiple myeloma (MM) involving standard therapy (ST). Recent studies suggest that dose …

Background Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has
been shown in preclinical and phase 1 studies to have antimyeloma activity. Methods In this …

Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the
treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 …

Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates and …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene
autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple …